SAVENE

This brand name is authorized in Austria, Croatia, Cyprus, Estonia, Finland, France, Ireland, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug SAVENE contains one active pharmaceutical ingredient (API):

1	Dexrazoxane UNII 5346058Q7S - DEXRAZOXANE HYDROCHLORIDE
	Dexrazoxane has two major mechanisms of action, chelation of iron and inhibition of topoisomerase II. It is not known to what extent each of these mechanisms contributes to the preventive effect on tissue destruction following anthracycline extravasation.
	Read more about Dexrazoxane

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SAVENE Powder and solvent for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V03AF02	Dexrazoxane	V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AF Detoxifying agents for antineoplastic treatment
Discover more medicines within V03AF02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1260335
ES	Centro de información online de medicamentos de la AEMPS	06350001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	101064
FR	Base de données publique des médicaments	62361751
GB	Medicines & Healthcare Products Regulatory Agency	109376
IT	Agenzia del Farmaco	037752019
JP	医薬品医療機器総合機構	3929410D1022
LT	Valstybinė vaistų kontrolės tarnyba	1058074
NL	Z-Index G-Standaard, PRK	82090
PL	Rejestru Produktów Leczniczych	100163294
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W56769001